Drugs / Vatalinib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00426452 | Jul 2006 → ? | — | Novartis | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vatalinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00426452 ↗ |
| Known as | PTK787/ZK 222584 | “A Phase IB, Open Label, Single Center, Drug-drug Interaction Study of Oral 1250 mg of PTK787/ZK 222584 Administered Under Fasting and Fed Conditions With a Proton-pump...” NCT00426452 ↗ |
| Route | Oral | “Oral 1250 mg of Vatalinib Administered Under Fasting and Fed Conditions” NCT00426452 ↗ |